UPMC Hillman Cancer Center and South Carolina Oncology Associates participated in Integra Connect's Quality Initiatives to identify gaps in cancer care and accelerate precision oncology adoptionWEST PALM BEACH, Fla., Oct. 24, 2023 /PRNewswire/ -- Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023.

UPMC Hillman癌症中心和南卡罗来纳州肿瘤协会参与了Integra Connect的质量计划，以确定癌症护理方面的差距并加速精确肿瘤学的采用West PALM BEACH，Fla。，2023年10月24日/PRNewswire/-Integra Connect，LLC。，领先的专业护理价值型精准医学解决方案和服务提供商，今天宣布了2023年10月27日至28日在2023年美国临床肿瘤学会（ASCO）质量护理研讨会期间将发表的三项研究结果。

The findings from these three studies – two done in conjunction with UPMC Hillman Cancer Center in Pittsburgh, PA and one done in conjunction with South Carolina Oncology Associates (SCOA) – emphasize the critical role quality initiatives play in identifying gaps in care and driving action to improve patient outcomes.

这三项研究的结果-两项与宾夕法尼亚州匹兹堡的UPMC Hillman癌症中心合作完成，另一项与南卡罗来纳州肿瘤协会（SCOA）合作完成-强调了质量倡议在确定护理和驾驶行动方面的差距方面发挥的关键作用改善患者预后。

Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023..

所有三张海报的调查结果将于2023年10月28日上午7:00至8:00在美国临床肿瘤学会优质护理研讨会上发表，然后于2023年10月28日上午11:45至下午1:00再次发表。。

Continue Reading

继续阅读

'As cancer research advances, there is a pressing need to understand the real-world adoption of standards of care for patients and how new scientific advances can improve providers' abilities to deliver patients the right treatment, at the right time, at the right dose and at the right price,' said Jeffrey A.

“随着癌症研究的进展，迫切需要了解现实世界中患者护理标准的采用情况，以及新的科学进步如何提高提供者在正确的时间，正确的剂量和正确的价格下为患者提供正确治疗的能力，”杰弗里a说。

Scott, MD, Chief Medical Officer and President of Population Health Solutions at Integra Connect. 'These studies with UPMC Hillman and SCOA demonstrate our shared commitment to helping providers transform cancer care, enhance testing rates, and ultimately move our industry toward individualized, precision medicine for each and every patient.'.

Scott，医学博士，Integra Connect的首席医疗官和人口健康解决方案总裁UPMC Hillman和SCOA的这些研究表明，我们共同致力于帮助提供者改变癌症护理，提高检测率，并最终将我们的行业推向每个患者的个性化精准医学。

Integra Connect to Present Key Clinical Research at the ASCO Quality Care Symposium

Integra Connect在ASCO质量护理研讨会上展示关键临床研究

Post this

发布这个

The studies were conducted with Integra Connect as part of its Quality Initiatives program, which is designed to help oncology practices, cancer institutes, and health systems make well-informed clinical decisions to ensure patients are receiving the best possible care. Integra Connect does this by bringing together clinical data from disparate systems and sources, organizing the information into complete, longitudinal patient journeys, and conducting in-depth analyses with its AI-enabled solutions.

这些研究是与Integra Connect一起进行的，作为其质量计划计划的一部分，该计划旨在帮助肿瘤学实践，癌症研究所和卫生系统做出明智的临床决策，以确保患者获得最佳护理。Integra Connect通过汇集来自不同系统和来源的临床数据，将信息组织成完整的纵向患者旅程，并通过其支持AI的解决方案进行深入分析来实现这一目标。

The research highlights testing and treatment decisions compared to standards in care, as well as ways to improve patient outcomes and reduce unwarranted variations in testing and treatment. .

该研究强调了与护理标准相比的测试和治疗决策，以及改善患者预后和减少测试和治疗中不必要的变化的方法。 .

UPMC Hillman Cancer Center and Integra Connect Identify Potential Gaps in Care for Patients with Non-Small Cell Lung Cancer and Prostate CancerUPMC Hillman elected to participate in quality initiatives with Integra Connect as a way to identify potential barriers to care and generate better outcomes for patients being treated for stage III non-small-cell lung cancer (NSCLC) and homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC).

UPMC Hillman癌症中心和Integra Connect确定非小细胞肺癌和前列腺癌患者护理方面的潜在差距PMC Hillman选择与Integra Connect一起参与质量计划，以确定潜在的护理障碍并为患者带来更好的结果正在接受III期非小细胞肺癌（NSCLC）和同源治疗的患者重组修复（HRR）突变的转移性去势抵抗性前列腺癌（mCRPC）。

Over the course of two studies, UPMC Hillman leadership was alerted to potential areas in which their providers' could deliver more precise cancer care. For the study in patients with stage III NSCLC, when patients were put on immunotherapy within 14 days after chemo-radiation therapy there was an improvement in overall survival compared to patients who initiated treatment later on.

在两项研究过程中，UPMC Hillman领导层被告知其提供者可以提供更精确的癌症护理的潜在领域。对于III期NSCLC患者的研究，当患者在化疗放疗后14天内接受免疫治疗时，与后来开始治疗的患者相比，总生存期有所改善。

For the study in patients with mCRPC, rates of HRR testing, HRR positivity, and PARPi use HRRm mCRPC patients at UPMC were analyzed by Integra Connect. As a result of the initial analyses and practice interventions, there was a 33% relative increase in HRR testing, with the number of HRRm mCRPC patients being treated with a PARPi increasing from 60% to 68%.

对于mCRPC患者的研究，通过Integra Connect分析UPMC的HRR检测率，HRR阳性率和PARPi使用HRRm-mCRPC患者。作为初步分析和实践干预的结果，HRR测试相对增加了33%，用PARPi治疗的HRRm-mCRPC患者数量从60%增加到68%。

Overall, both projects leveraging Quality Initiatives helped to move clinical decisions toward a more patient-centered, value-driven approach, such as effective use of the right therapy, faster time to treatment, and increased use of genomic testing. 'Advancements in cancer care are happening faster than ever and it is vital that clinicians have access to the latest insights available to inform personalized care,' said Rushir J.

总体而言，这两个利用质量举措的项目都有助于将临床决策转向更加以患者为中心，价值驱动的方法，例如有效使用正确的治疗方法，加快治疗时间并增加基因组测试的使用。Rushir J说：“癌症治疗的进展比以往任何时候都快，临床医生必须获得可用于个性化护理的最新见解。

Choksi, MD, Assistant Medical Director, Medical Oncology Network at UPMC Hillman Cancer Center. 'Through this quality initiative and collabo.

Choksi，医学博士，UPMC希尔曼癌症中心肿瘤内科网络助理医学主任通过这个质量倡议和合作。

'Management and treatment of patients (pts) with stage III unresected non-small cell lung cancer (NSCLC) at UPMC: A quality initiative by Integra Connect PrecisionQ.' (Abstract #428016 | Poster N2)

“UPMC III期未切除非小细胞肺癌（NSCLC）患者的管理和治疗：Integra Connect PrecisionQ的质量倡议。”（摘要＃428016＃海报N2）

'Understanding testing for and treatment of homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC): A quality initiative by Integra Connect PrecisionQ.' (Abstract #428270 | Poster N4)

“了解同源重组修复（HRR）突变的转移性去势抵抗性前列腺癌（mCRPC）的测试和治疗：Integra Connect PrecisionQ的质量计划。”（摘要＃428270＃海报N4）

Integra Connect and South Carolina Oncology Associates Highlight the Need for Genomic Testing as a Standard of CareSouth Carolina Oncology Associates (SCOA) and Integra Connect conducted a research study to assess the rates of molecular testing and biomarker positivity in patients with stage IV NSCLC, comparing those with squamous histology to those with non-squamous histology.

Integra Connect和南卡罗来纳州肿瘤协会强调需要进行基因组检测作为护理标准南卡罗来纳州肿瘤协会（SCOA）和Integra Connect进行了一项研究，以评估IV期NSCLC患者的分子检测率和生物标志物阳性率，比较那些鳞状组织学与非鳞状组织学。

The study utilized the Integra Connect de-identified database of more than 2 million cancer patients, of which a subset included 3,889 stage IV NSCLC patients for testing rate comparisons and 6,303 stage IV NSCLC patients for positivity rate assessments. The results showed significantly lower testing rates in patients with squamous histology for various biomarkers compared to patients with non-squamous histology, with corresponding differences in positivity rates.

该研究利用Integra Connect去识别的超过200万癌症患者的数据库，其中一个子集包括3889名IV期NSCLC患者用于测试率比较和6303名IV期NSCLC患者用于阳性率评估。结果显示，与非鳞状组织学患者相比，各种生物标志物的鳞状组织学患者的检测率显着降低，阳性率也相应不同。

Overall, these findings suggest a critical need for providers in all settings and payers to work collaboratively to ensure genomic testing is performed without barriers and biases, to ensure that all patients receive the right treatment.'The results from this study underscores the importance of bridging the testing divide between cancer subtypes by ensuring equitable access to the latest targeted treatments,' said Fred J.

总体而言，这些发现表明，迫切需要所有环境中的提供者和付款人合作，以确保在没有障碍和偏见的情况下进行基因组测试，以确保所有患者都能得到正确的治疗Fred J.说，这项研究的结果强调了通过确保公平获得最新的靶向治疗来弥合癌症亚型之间的测试鸿沟的重要性。

Kudrik, MD, President at South Carolina Oncology Associates. 'By ensuring access to genomic testing, without burdening the patient with complex routes to testing, we not only enhance the chances of better outcomes but also provide improved quality of life for patients.'Abstract details are as follows:.

Kudrik，医学博士，南卡罗来纳州肿瘤协会主席通过确保获得基因组测试，而不会给患者带来复杂的测试途径负担，我们不仅可以提高获得更好结果的机会，而且还可以改善患者的生活质量摘要详情如下：。

'Comparison of molecular testing rates and biomarker positivity by histology among patients (pts) with stage IV non-small cell lung cancer (NSCLC): A quality initiative by Integra Connect PrecisionQ.' (Abstract #428272 | Poster N5)

“IV期非小细胞肺癌（NSCLC）患者组织学分子检测率和生物标志物阳性率的比较：Integra Connect PrecisionQ的质量倡议。”（摘要＃428272＃海报N5）

This latest research builds on the 12 posters and abstracts that Integra Connected presented at ASCO 2023, and the organization's commitment to advancing precision oncology at scale. For more information on Integra Connect's research, please visit: https://campaign.integraconnect.com/latest-research?hs_preview=VppklfVH-115340478102.SOURCE Integra Connect.

这项最新研究基于Integra在ASCO 2023上发表的12篇海报和摘要，以及该组织致力于大规模推进精确肿瘤学的承诺。有关Integra Connect研究的更多信息，请访问：https://campaign.integraconnect.com/latest-research?hs_preview=VppklfVH-115340478102.源Integra Connect。